Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06874335

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Led by Biohaven Therapeutics Ltd. · Updated on 2026-05-13

95

Participants Needed

13

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.

CONDITIONS

Official Title

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent approved by an ethics committee
  • Age 18 years or older
  • Willing to provide tumor tissue collected within 90 days prior to treatment
  • Have progressed following or are intolerant to standard therapies or have no available standard treatment
  • Have histologically or cytologically confirmed locally advanced or metastatic solid tumors including urothelial cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, or other solid tumors with FGFR3 alterations
  • Measurable tumors per RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Acceptable liver function (bilirubin ≤1.5× ULN, AST/ALT/alkaline phosphatase ≤2.5× ULN or ≤5× ULN if liver metastases present)
  • Acceptable kidney function (serum creatinine ≤1.5× ULN or creatinine clearance ≥50 mL/min)
  • Acceptable blood counts (neutrophils ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥9 g/dL)
  • Negative pregnancy test if woman of childbearing potential
  • Agreement to use effective contraception during and after the study (7 months for women, 4 months for men)
Not Eligible

You will not qualify if you...

  • Prior treatment with antibody drug conjugates containing topoisomerase-I inhibitors
  • Significant heart disease including recent heart attack or unstable angina within 6 months, severe heart failure, uncontrolled arrhythmia, or severe aortic stenosis
  • Active infections requiring systemic therapy
  • Primary CNS tumors, untreated or active brain metastases (treated stable brain metastases may be allowed)
  • Pregnant or nursing women
  • Recent cancer therapy or major surgery within specified time frames before study start
  • Unrecovered toxicities from prior treatments except alopecia and vitiligo
  • Significant eye abnormalities increasing risk of toxicity
  • Active infections with HIV, HTLV-1, hepatitis B or C unless controlled per protocol
  • Active second malignancy unless fully treated and low risk of recurrence
  • Inability to comply with study procedures or treatment
  • Sensitivity to BHV-1530 or its components
  • History or active interstitial lung disease requiring steroids
  • Need for supplemental oxygen for daily activities
  • Recent live vaccine within 4 weeks before starting study drug

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Site-107

Denver, Colorado, United States, 80218

Actively Recruiting

2

Site-108

Lake Mary, Florida, United States, 32746

Withdrawn

3

Site-121

Miami, Florida, United States, 33136

Actively Recruiting

4

Site-110

Detroit, Michigan, United States, 48201

Actively Recruiting

5

Site-115

Durham, North Carolina, United States, 27710

Actively Recruiting

6

Site-112

Myrtle Beach, South Carolina, United States, 29572

Actively Recruiting

7

Site-116

Nashville, Tennessee, United States, 37203

Actively Recruiting

8

Site-103

Austin, Texas, United States, 78758

Actively Recruiting

9

Site-104

Houston, Texas, United States, 77030

Actively Recruiting

10

Site-101

Irving, Texas, United States, 75039

Actively Recruiting

11

Site-105

San Antonio, Texas, United States, 78229

Actively Recruiting

12

Site-106

West Valley City, Utah, United States, 84119

Actively Recruiting

13

Site-102

Fairfax, Virginia, United States, 22031

Actively Recruiting

Loading map...

Research Team

C

Chief Medical Officer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | DecenTrialz